Skip to main content
All lobbying filings

The Cigna Group and Subsidiaries (Formerly Cigna Corporation and Subsidiaries)

The Cigna Group and Subsidiaries (Formerly Cigna Corporation and Subsidiaries) filed a Q1 report for The Cigna Group and Subsidiaries (Formerly Cigna Corporation and Subsidiaries) on April 21, 2025.

Lobbying for The Cigna Group and Subsidiaries (Formerly Cigna Corporation and Subsidiaries)

As filed: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES).

All filings by The Cigna Group and Subsidiaries (Formerly Cigna Corporation and Subsidiaries) · Everything The Cigna Group and Subsidiaries (Formerly Cigna Corporation and Subsidiaries) has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 21, 2025
Expenses
$3,460,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Medicare/Medicaid

P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023.

Health Issues

S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) included in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA).

Defense

Pharmacy issues related to the National Defense Authorization Act, FY2026.

Pharmacy

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S. 526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act.

Budget/Appropriations

Issues related to H.Con.Res. 14/S.Con.Res. 7 (Establishing the congressional budget for the United States Government for fiscal year 2025) and budget reconciliation; H.R. 1968, Full-Year Continuing Appropriations and Extensions Act, 2025.

 Bills named in this filing 14
  • H.R. 4189
    To direct the Secretary of the Navy to recognize certain aspects of the National Navy UDT-SEAL Museum in Fort Pierce, F…
  • S. 2016
    Chugach Alaska Land Exchange Oil Spill Recovery Act of 2025
  • S. 864
    HELP Copays Act
  • H.R. 247
    Health Care Affordability Act of 2025
  • S. 1542
    DRUG Act
  • H.R. 2214
    DRUG Act
  • H.R. 5378
    Lower Costs, More Transparency Act
  • S. 1339
    Pharmacy Benefit Manager Reform Act
  • S. 526
    Pharmacy Benefit Manager Transparency Act of 2025
  • S. 1040
    Drug Competition Enhancement Act
  • S. 1041
    Affordable Prescriptions for Patients Act
  • H. Con. Res. 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • S. Con. Res. 7
    An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal ye…
  • H.R. 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem